The Changes in the Text
On page 34, we state “Clinical trial testing short-term efficacy of SierraSil at doses of 2 and 3 g per day failed to show sustained benefits over placebo, and iron toxicity has been reported.74” In fact, although this formulation contains a warning about iron toxicity in children younger than 6 years, we are unaware of studies that have reported iron toxicity in adult subjects. The reference (Miller et al.) makes no mention of iron toxicity.
On page 37, we state “Avoca ASU (ASU-NMX1000, Nutramax Laboratories Inc., Edgewood, MD, USA)”. In fact, this should state “Avoca ASU (ASU-OptiMSM, Nutramax Laboratories Inc., Edgewood, MD, USA).”
On page 37, we state “Avoca ASU, a combination of ASU and glucosamine sulfate, has been shown to suppress TNFα, IL1β, COX2, iNOS, PGE2, NFκB activation and nitrite production in articular chondrocytes and monocytes/macrophages, reducing pain and inflammation in OA patients.115,116,124” In fact, this should state “Avoca ASU, a combination of ASU and glucosamine hydrochloride, has been shown to suppress TNFα, IL1β, COX2, iNOS, PGE2, NFκB activation and nitrite production in articular chondrocytes and monocytes/macrophages, reducing pain and inflammation in OA patients.115,116,124”
On page 37, we state “Avoca ASU that contains glucosamine can induce allergic reaction in people with shellfish allergy. Even in very small quantities, these people may experience mild symptoms, such as hives or nasal congestion, or more-severe, even life-threatening symptoms.” In fact, Avoca ASU contains non-shellfish glucosamine hydrochloride. The glucosamine hydrochloride in Avoca ASU is plant based, and therefore would have no risk of side effects in people with shellfish allergy.
On page 38, Table 3, “Nutramax” has been misspelled as “Nuramax.”
Table 3.
Content Analysis of Supplements Containing Avocado Soybean Unsaponifiable.
| Company/Manufacturer | Brand name | Dosage form | Other ingredients | Excipients on the label |
|---|---|---|---|---|
| Dr. Theo’s Official | Avosoy | ASU | Vitamin C, vitamin E | c, croscarmellose, SDO, gum acacia, vegetable |
| Manganese | SA | |||
| Dr. Theo’s Official | Avosoy Complete | ASU, glucosamine | Vitamin C, vitamin E | c, gum Arabic, SDO, SA, shellfish-free |
| HCl, porcine chondroitin sulfate | Manganese, calcium | |||
| Helseudsalg Faaborg Denmark | Avosol | ASU | Vitamin C | Glucose syrup, oxgelatin, SPI, extract rich in tocopherol, SDO, Mg salts from fatty acids |
| Laboratoires Expanscience, Pharmascience, Pharma Investi, Solvay Farma, Siegfried Rhein, SAdeCV | Piascledine 300 | ASU | BHT, CAS | Gelatin, polysorbate 80, TDO, erythrosine, yellow iron oxide |
| Maximum International | Maximize, ASU | SierraSil, iron, CC, DCP | MCC, maltodextrin, croscarmellose Na | SDO, SA, HPMC, HPC, MS, PEG |
| Nutramax Laboratories, Inc. | Avoca ASU | Glucosamine HCl, ASU, DCP MSM | Decaffeinated green tea leaf extract | SPI, tocopherols, MCC, MS, SDO, non-shellfish, gluten-free |
| Nutramax Laboratories, Inc. | Cosamin ASU | Glucosamine HCl, Na chondroitin sulfate, ASU | Decaffeinated green tea leaf extract | Gelatin, SPI, tocopherols, SDO, gum resin, MS, TDO, yellow 5 and blue 1 |
| Pharmin, USA, LLC. | Arthrocen | ASU | Persea gratissima, Glycine max, preservative free, gelatin fines, | Silica, magnesium stearate (E470b from vegetable oil) |
| Swanson Health Products | AvoVida | ASU | Phytosterols (β-sitosterol, campesterol, stigmasterol) | SPI, mixed tocopherols, silica, MCC, gelatin, MS, rice flour |
Abbreviations: ASU = avocado/soybean unsaponifiable; BHT = butylated hydroxytoluene; CC = calcium carbonate; c = cellulose; CAS = colloidal anhydrous silica; DCP = dicalcium phosphate; HPC = hydroxypropyl cellulose; HPMC = hydroxypropyl methylcellulose; MS = magnesium stearate; Mg = magnesium; MSM = methylsulfonylmethane; MCC = microcrystalline cellulose; PEG = polyethylene glycol; SDO = silicon dioxide; Na = sodium; SPI = soy protein isolate; SA = stearic acid; TDO = titanium dioxide.
On page 39, Table 4, we state “references 106, 129, 130.” In fact, references are 106, 128, 130.
On page 37, we state, “Further prospective multicenter studies are warranted to investigate whether other microscopic colitis cases129 are observed in patients treated with Piascledine.” In fact, we conclude that further prospective multicenter studies are warranted to investigate microscopic colitis cases; however, this is not specific to the use of Piascledine.
On page 39, in the Declaration of Conflicting Interests, we state “Simrit Bhatti and Dr. Ramin Goudarzi are employees of Formulation Technology Inc. and Pharmin USA, LLC, respectively.” In fact, Simrit Bhatti is an employee of Formulation Technology Inc.; however, Dr. Ramin Goudarzi is the Principal of Pharmin USA, LLC.”
The changes in Table 3, page 39, are as follows:
Acknowledgments
The authors acknowledge the above factual errors and misspellings.